In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 27 of the 34 sources its claims cite were checked for support.
Abstract
The resistance of Candida albicans to azole drugs represents a great global challenge. This study investigates the potential fungicidal effects of atorvastatin (ATO) combinations with fluconazole (FLU), itraconazole (ITR), ketoconazole (KET) and voriconazole (VOR) against thirty-four multidrug-resistant (MDR) C. albicans using checkerboard and time-kill methods. Results showed that 94.12% of these isolates were MDR to ≥ two azole drugs, whereas 5.88% of them were susceptible to azole drugs. The tested isolates exhibited high resistance rates to FLU (58.82%), ITR (52.94%), VOR (47.06%) and KET (35.29%), whereas only three representative (8.82%) isolates were resistant to all tested azoles. Remarkably, the inhibition zones of these isolates were increased at least twofold with the presence of ATO, which interacted in a synergistic (FIC index ≤ 0.5) manner with tested azoles. In silico docking study of ATO and the four azole drugs were performed against the Lanosterol 14-alpha demethylase enzyme (ERG11) of C. albicans. Results showed that the mechanism of action of ATO against C. albicans is similar to that of azole compounds, with a docking score (−4.901) lower than azole drugs (≥5.0) due to the formation a single H-bond with Asp 225 and a pi–pi interaction with Thr 229. Importantly, ATO combinations with ITR, VOR and KET achieved fungicidal effects (≥ 3 Log10 cfu/ml reduction) against the representative isolates, whereas a fungistatic effect (≤ 3 Log10 cfu/ml reduction) was observed with FLU combination. Thus, the combination of ATO with azole drugs could be promising options for treating C. albicans infection.
Overview
CoChat Summary
TL;DR
Atorvastatin (ATO) showed antifungal activity against multidrug-resistant *Candida albicans* and synergized with fluconazole, itraconazole, ketoconazole, and voriconazole in vitro. ATO/azole combinations reduced azole MICs below susceptible breakpoints and produced fungicidal effects with ITR, VOR, and KET, while ATO/FLU was fungistatic.
Key findings
- Among 34 *C. albicans* isolates, 94.12% (32/34) were multidrug resistant to ≥ two azole drugs, 5.88% (2/34) were susceptible to all tested drugs, and 8.82% (3/34) were resistant to all tested azoles. Azole resistance rates were FLU 58.82%, ITR 52.94%, VOR 47.06%, and KET 35.29%.
- ATO increased azole inhibition zones at least twofold. Checkerboard testing showed all ATO/azole combinations were synergistic (FIC index ≤ 0.5), with four-fold MIC reductions; MICs decreased from 16–32 to 4.0 mg/l for ATO, 8.0–16 to 1.0–4.0 mg/l for FLU, 1.6–3.2 to 0.2–0.4 mg/l for ITR, 2.0–4.0 to 0.25–0.5 mg/l for VOR, and 1.6–12.8 to 0.4–1.6 mg/l for KET.
- In time-kill assays, ATO alone at MIC levels produced ≥3 Log10 cfu/ml reductions against representative isolates. ATO (4 mg/l) combined with ITR, VOR, or KET produced synergistic fungicidal effects after 24 h (3.0–3.7 Log10 cfu/ml reduction), whereas ATO/FLU produced a 2.34–2.7 Log10 cfu/ml reduction, reported as fungistatic.
- Docking against *C. albicans* ERG11 gave ATO a score of −4.901, with a single H-bond to Asp 225 and a pi-pi interaction with His 310 in the Results; ATO’s HMG-CoA reductase binding score was −5.472 with two H-bonds to Gly (C) 715 and Ser (C) 720.
Methods
- Thirty-four *C. albicans* clinical isolates from Kasr El-Ainy Hospital, Cairo, Egypt (2019–2020), from urine, sputum, pus, wound, and blood, were purified on Chromagar Candida and stored.
- Susceptibility was tested by CLSI broth microdilution MIC for amphotericin B, FLU, ITR, KET, and VOR; ATO MIC was determined against representative isolates. Disc diffusion was performed on Mueller-Hinton agar with glucose and methylene blue (MHG) containing 0, 0.5, or 1.0 mg/l ATO.
- Synergy was assessed by checkerboard FIC index (synergism ≤ 0.5; indifference >0.5 to <4; antagonism >4) and time-kill assays in Sabouraud dextrose broth at 0 and 24 h. In silico docking used ERG11 (PDB: 5V5Z) and a homology model of HMG-CoA reductase (PDB: 3cd0) with Schrodinger Maestro/Glide.
Limitations
- Stated: the number of MDR *C. albicans* isolates was relatively low, and no reference azole-resistant *C. albicans* strains were used; the authors attribute this to COVID-19 quarantine conditions and unavailability of imported reference strains. They also state that further work is needed to confirm results and assess in vivo benefit.
- Evident from the text: the synergy and time-kill studies used only three representative isolates; the study is entirely in vitro; docking results are computational and not experimentally validated. The text also contains minor discrepancies, e.g., the abstract reports a pi-pi interaction with Thr 229 while the Results/Table report His 310, and the time-kill text reports a 4.13 Log10 reduction for CA3 while the table shows 3.14.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 3 Not checked · 50 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“At present, clinical isolates of Candida spp. are considered to be one of the highly resistant fungi to most traditional antifungal drugs(Costa-de-oliveira and Rodrigues 2020; Tan et al. 2021)”
What the sources say
- Disputedcites Costa-de-oliveira and Rodrigues 2020 matched to “Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal” (2020) sourceExperimental — accuracy not yet measured
The Conclusions (section 5; page unavailable) say that C. albicans has low in vitro resistance to antifungal drugs, contrary to describing Candida clinical isolates as highly resistant to most traditional antifungals. The review discusses how resistance can develop, but does not characterize it as generally high. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Partly supportedcites Tan et al. 2021 matched to “Antifungal Activity of Minocycline and Azoles Against Fluconazole-Resistant Candida Species” (2021) sourceExperimental — accuracy not yet measured
The Introduction reports emerging fluconazole resistance in Candida and high fluconazole resistance in C. auris. It also gives much lower resistance frequencies for several other Candida species and does not establish that clinical Candida isolates are highly resistant to most traditional antifungal drugs. The Methods describe a selected set of fluconazole-resistant clinical isolates, not clinical isolates generally. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Interestingly, atorvastatin is one of statin drugs has shown significant antifungal activity against different Candida species. particularly against C. albicans (Esfahani et al. 2019; Lima et al. 2019).”
What the sources say
- Partly supportedcites Esfahani et al. 2019 matched to “Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin” (2019) sourceExperimental — accuracy not yet measured
The Abstract Results report that all five Candida strains were sensitive to atorvastatin. They also report no statistically significant difference in sensitivity among strains, so the paper does not support singling out C. albicans as particularly susceptible. (LLM, conf=0.88)
- Partly supportedcites Lima et al. 2019 matched to “Are the Statins promising antifungal agents against invasive candidiasis?” (2019) sourceExperimental — accuracy not yet measured
Section 3.1 and Table 1 show atorvastatin activity against multiple Candida species, including C. albicans. But the paper describes its activity against all C. albicans samples tested as moderate, not significant; it uses “significant” for fluvastatin’s activity against C. albicans. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The obtained results are consistent with previous studies, which mentioned that there were synergistic interactions between statins and azole drugs against Candida spp. Saccharomyces cerevisiae and different filamentous fungi (Lorenz and Parks 1990; Chamilos et al. 2006; Nyilasi et al. 2010).”
What the sources say
- Partly supportedcites Lorenz and Parks 1990 matched to “Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae” (1990) sourceExperimental — accuracy not yet measured
The Results and Discussion report that lovastatin lowered the MICs of three azoles in S. cerevisiae, supporting the yeast portion of the claim. The paper does not report statin–azole synergy against Candida spp. or filamentous fungi; it mentions filamentous fungi only when describing another study. (LLM, conf=0.86)
- Partly supportedcites Chamilos et al. 2006 matched to “Lovastatin Has Significant Activity against Zygomycetes and Interacts Synergistically with Voriconazole” (2006) sourceExperimental — accuracy not yet measured
The Discussion reports statin–azole synergy against Candida and finds lovastatin–voriconazole synergy against the filamentous Zygomycetes tested. The Abstract mentions statin activity against Saccharomyces cerevisiae, but does not say the statin and an azole acted synergistically against it. Page numbers are not supplied for these passages. (LLM, conf=0.88)
- Partly supportedcites Nyilasi et al. 2010 matched to “In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi: Synergistic interactions between statins and azoles” (2010) sourceExperimental — accuracy not yet measured
The ‘Interactions between azoles and statins’ section reports synergistic combinations against Candida albicans and filamentous fungi, including Aspergillus fumigatus and Rhizopus oryzae. The Introduction lists the species studied but does not include Saccharomyces cerevisiae; that part of the citing sentence is not supported by this paper’s findings. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The synergism between ATO and azole drugs might be attributed to the combined action of these drugs in reducing fungal ergosterol synthesis, which led to increasing cell membrane permeability and increasing the penetration of azoles in the fungal cell (Chamilos et al. 2006; Nyilasi et al. 2010; Cabral et al. 2013; Lima et al. 2019).”
What the sources say
- Partly supportedcites Chamilos et al. 2006 matched to “Lovastatin Has Significant Activity against Zygomycetes and Interacts Synergistically with Voriconazole” (2006) sourceExperimental — accuracy not yet measured
The Discussion reports synergy between lovastatin and voriconazole and identifies sequential steps in ergosterol biosynthesis that statins and azoles inhibit. It calls that mechanism plausible rather than established. This paper tested lovastatin, not ATO, and does not report increased membrane permeability or azole penetration into fungal cells (Discussion; page not available). (LLM, conf=0.86)
- Partly supportedcites Nyilasi et al. 2010 matched to “In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi: Synergistic interactions between statins and azoles” (2010) sourceExperimental — accuracy not yet measured
The Introduction describes azoles as inhibiting a step in ergosterol biosynthesis, and the Interactions between azoles and statins section reports synergy for some ATO–azole combinations. The paper does not attribute that synergy to combined suppression of ergosterol synthesis or report increased membrane permeability and azole penetration. The indexed passages provide section labels but no page numbers. (LLM, conf=0.86)
- Partly supportedcites Cabral et al. 2013 matched to “Synergistic antifungal activity of statin–azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification” (2013) sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The same fungicidal effects were associated the combinations of Fluvastatin (Lima et al. 2019) or pitavastatin (Eldesouky et al. 2020) with azole drugs produced fungicidal effects against Candida ssp., especially C. albicans .”
What the sources say
- Partly supportedcites Lima et al. 2019 matched to “Are the Statins promising antifungal agents against invasive candidiasis?” (2019) sourceExperimental — accuracy not yet measured
Section 3.5 reports that fluvastatin combined synergistically with itraconazole, ketoconazole, and fluconazole against C. albicans. But the combination assay measured inhibition, not fungicidal activity; the paper reports fungicidal concentrations for fluvastatin tested alone. The cited results also do not establish the combination effect across Candida species. Pitavastatin is attributed to a different citation and is not judged here. (LLM, conf=0.88)
- Partly supportedcites Eldesouky et al. 2020 matched to “Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species” (2020) sourceExperimental — accuracy not yet measured
The Results and Discussion section reports that pitavastatin combined with fluconazole had synergistic inhibitory effects against several Candida species, including C. albicans; it also reports synergy with other azoles in some tested strains. It does not establish that these combinations were fungicidal. Fluvastatin is attached to a different citation in the citing sentence and is not judged here. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
33 more claims
Create a free account to see all 66 claims and to verify the 2 references still open.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 18
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, statins may stimulate farnesol‐dependent pathogenicity factors, such as the transition from yeast to hyphae and biofilm formation, which are key resistance mechanisms in fungi [115].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies suggest that this statin may exert its antifungal effects through various mechanisms, contributing to its significant activity against different Candida strains, particularly C. albicans [115].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [115]
The cited source says what the claim attributes to it.
In the citing paper
“ATV has also demonstrated broad synergistic interactions with fluconazole, itraconazole, voriconazole, and ketoconazole against multidrug‐resistant C. albicans , suggesting superior potential relative to other statins [115].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Discussion · p. 7
“In the present study, 94.12% (32/34) of the tested C. albicans isolates were MDR resistant to at least two different azole drugs”
§ Results · p. 5
“| Resistant | 18 (52.94) | 20 (58.82) | 18 (52.94) | 16 (47.06) | 12 (35.29) | 3 (8.82) |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 7
“Whereas, the combination of ATO (4 mg/l) with FLU exhibited synergistic and fungicidal effects after 24 h of exposure, with reduction range (2.34-2.7 Log 10 cfu/ml) of the initial inoculum.”
§ Time-Kill kinetic Assay · p. 5
“Fungistatic and fungicidal effects were defined as <3 Log 10 and ≥3 Log 10 reductions in cfu/ml from the starting inoculum, respectively (Scorneaux et al. 2017).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Abstract · p. 1
“a pi-pi interaction with Thr 229”
§ Results · p. 6
“a pi-pi interaction with His 310”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| ATO / VOR | 32/4.0 | 16/4.0 | 16/2.0 | 4.0/0.5 | 4.0/0.5 | 4.0/0.25 | 0.125/0.125 | 0.25/0.125 | 0.125/0.250 | 0.25 (S) | 0.375 (S) | 0.375 (S) |”
Reported 0.125 · recomputed 0.25
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 7
“with reduction range (2.34-2.7 Log 10 cfu/ml) of the initial inoculum.”
§ Discussion · p. 10
“| ATO/FLU | 4.0/4.0 | 4.0/2.0 | 4.0/1.0 | 4.70 | 4.81 | 4.60 | 2.00 | 2.00 | 2.18 | - 2.70 | - 2.81 | - 2.43 |”
4 more findings
Create a free account to see every finding of this check.
Citations
Cites
SWISS-MODEL: homology modelling of protein structures and complexes
Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T. A. P., Rempfer, C., Bordoli, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky427 · Cited by 13,067
Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953
HHblits: lightning-fast iterative protein sequence searching by HMM-HMM alignment
Remmert, M., Biegert, A., Hauser, A., & Söding, J. (2012) · Nature Methods · doi:10.1038/nmeth.1818 · Cited by 2,288
Toward the estimation of the absolute quality of individual protein structure models
Benkert, P., Biasini, M., & Schwede, T. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btq662 · Cited by 2,260
Guex, N., Peitsch, M. C., & Schwede, T. (2009) · ELECTROPHORESIS · doi:10.1002/elps.200900140 · Cited by 2,097
Cappelletti, M., Presentato, A., Milazzo, G., Turner, R. J., Fedi, S., Frascari, D., & Zannoni, D. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00393 · Cited by 1,776
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Bertoni, M., Kiefer, F., Biasini, M., Bordoli, L., & Schwede, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-09654-8 · Cited by 866
Resistance of Candida to azoles and echinocandins worldwide
Pristov, K. E., & Ghannoum, M. A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.03.028 · Cited by 706
Evaluation of different detection methods of biofilm formation in the clinical isolates
Hassan, A., Usman, J., Kaleem, F., Omair, M., Khalid, A., & Iqbal, M. (2011) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(11)70197-0 · Cited by 577
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
Candidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416 · cited 1×
“Despite the necessity of the discovery of novel antifungals, the financial resources for this field of research are still restricted and the approval process is already long and expensive (Sanglard 2016; Campoy and Adrio 2017; Wall and Lopez-Ribot 2020).”
BackgroundCampoy, S., & Adrio, J. L. (2017) · Reactions weekly · doi:10.1007/s40278-017-38968-3 · Cited by 401
Koushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08791-9 · Cited by 382
Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens
Friedman, D. Z. P., & Schwartz, I. S. (2019) · Journal of Fungi · doi:10.3390/jof5030067 · Cited by 357
Continuous scanning for Bragg coherent X-ray imaging
Li, N., Dupraz, M., Wu, L., Leake, S. J., Resta, A., Carnis, J., Labat, S., Almog, E., Rabkin, E., Favre-Nicolin, V., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69678-5 · Cited by 321
The IMPROV Study Group (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1276-2 · Cited by 277
The Multifunctional Fungal Ergosterol
Rodrigues, M. L. (2018) · mBio · doi:10.1128/mbio.01755-18 · Cited by 275 · cited 1×
“2015; Rodrigues 2018; Lima et al.”
Costa-de-Oliveira, S., & Rodrigues, A. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020154 · Cited by 229
Aspiring Antifungals: Review of Current Antifungal Pipeline Developments
Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225
Upregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors
Henry, K. W., Nickels, J. T., & Edlind, T. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2693-2700.2000 · Cited by 216
Evaluation of different detection methods of biofilm formation in the clinical isolates
Hassan, A., Usman, J., Kaleem, F., et al. (2011) · The Brazilian Journal of Infectious Diseases · doi:10.1590/s1413-86702011000400002 · Cited by 214
Peer education for HIV prevention among high-risk groups: a systematic review and meta-analysis
He, J., Wang, Y., Du, Z., Liao, J., He, N., & Hao, Y. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05003-9 · Cited by 180
Espinel-Ingroff, A., Colombo, A. L., Córdoba, S. B., Dufresne, P. J., Fuller, J., Ghannoum, M. A., González, G. M., Guarro, J., Kidd, S. E., Meis, J. F. G. M., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02456-15 · Cited by 160
Clinical implications for statin pleiotropy
Liao, J. K. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191913.16321.60 · Cited by 139 · cited 1×
“These finding are consistent with previous study, which revealed that a research on statin drugs originated with the intention of developing new antimicrobial agents as the inhibition of β-Hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase, results in the death of microorganisms (Liao 2005).”
ResultMultidrug resistance in fungi: regulation of transporter-encoding gene expression
Paul, S., & Moye-Rowley, W. S. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00143 · Cited by 137
Chamilos, G., Lewis, R. E., & Kontoyiannis, D. P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.96-103.2006 · Cited by 121
Keniya, M. V., Sabherwal, M., Wilson, R. K., Woods, M. A., Sagatova, A. A., Tyndall, J. D. A., & Monk, B. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01134-18 · Cited by 115
The Innovative Potential of Statins in Cancer: New Targets for New Therapies
Di Bello, E., Zwergel, C., Mai, A., & Valente, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00516 · Cited by 105
Lorenz, R. T., & Parks, L. W. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.9.1660 · Cited by 104
SCY-078 is fungicidal against Candida species in time-kill studies
Scorneaux, B., Angulo, D., Borroto-Esoda, K., Ghannoum, M., Peel, M., & Wring, S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01961-16 · Cited by 88
Nyilasi, I., Kocsubé, S., Krizsán, K., Galgóczy, L., Pesti, M., Papp, T., & Vágvölgyi, C. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.01972.x · Cited by 83
Statins: antimicrobial resistance breakers or makers?
Ko, H. H. T., Lareu, R. R., Dix, B. R., & Hughes, J. D. (2017) · PeerJ · doi:10.7717/peerj.3952 · Cited by 83
Kim, J. H., Cheng, L. W., Chan, K. L., Tam, C. C., Mahoney, N., Friedman, M., Shilman, M. M., & Land, K. M. (2020) · Antibiotics · doi:10.3390/antibiotics9110812 · Cited by 71
Synergistic Antibacterial Effect between Silibinin and Antibiotics in Oral Bacteria
Lee, Y., Jang, K., & Cha, J. (2011) · BioMed Research International · doi:10.1155/2012/618081 · Cited by 68
Sarver, R. W., Bills, E., Bolton, G., Bratton, L. D., Caspers, N. L., Dunbar, J. B., Harris, M. S., Hutchings, R. H., Kennedy, R. M., Larsen, S. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7015057 · Cited by 65
Are the Statins promising antifungal agents against invasive candidiasis?
Lima, W. G., Alves-Nascimento, L. A., Andrade, J. T., Vieira, L., de Azambuja Ribeiro, R. I. M., Thomé, R. G., dos Santos, H. B., Ferreira, J. M. S., & Soares, A. C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.076 · Cited by 65
Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity
Wall, G., & Lopez-Ribot, J. L. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00924-20 · Cited by 62
Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments
Juárez-López, D., & Schcolnik‐Cabrera, A. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.10.021 · Cited by 59
Gupta, A., Stokes, W., Eguchi, M., Hararah, M., Amini, A., Mueller, A., Morgan, R., Bradley, C., Raben, D., McDermott, J., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.01.019 · Cited by 57
Eldesouky, H. E., Salama, E. A., Li, X., Hazbun, T. R., Mayhoub, A. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-64571-7 · Cited by 55
Cabral, M. E., Figueroa, L. I. C., & Fariña, J. I. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.09.006 · Cited by 54
Zhang, J., Liu, J., Liu, F., Xia, Y., Wang, J., Liu, X., Zhang, Z., Zhu, N., Yan‐Yan, Ying, Y., et al. (2014) · Mycoses · doi:10.1111/myc.12204 · Cited by 50
Blind estimation and correction of microarray batch effect
Varma, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231446 · Cited by 49
Escobar, I. E., White, A., Kim, W., & Mylonakis, E. E. (2020) · Antibiotics · doi:10.3390/antibiotics9100665 · Cited by 48
Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis
Nagashima, M., Yamagishi, Y., & Mikamo, H. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.08.008 · Cited by 47
How to treat fungal infections in ICU patients
Matthaiou, D. K., Christodoulopoulou, T. C., & Dimοpoulos, G. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0934-8 · Cited by 44
Khairat, S. M., Sayed, A. M., Nabih, M., Soliman, N. S., & Hassan, Y. M. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s196972 · Cited by 35
Nyilasi, I., Kocsubé, S., Pesti, M., Lukács, G., Papp, T., & Vágvölgyi, C. (2010) · Journal of Medical Microbiology · doi:10.1099/jmm.0.013946-0 · Cited by 35
Influence of β-Lactam Infusion Strategy on Acute Kidney Injury
Cotner, S. E., Rutter, W. C., Burgess, D. R., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00871-17 · Cited by 34
Li, H., Zhang, W., Chen, Z., Shi, W., & Sun, S. (2014) · FEMS Yeast Research · doi:10.1111/1567-1364.12163 · Cited by 33
Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin
Nasr Esfahani, A., Golestannejad, Z., Khozeimeh, F., Dehghan, P., Maheronnaghsh, M., & Zarei, Z. (2019) · Medicine and Pharmacy Reports · doi:10.15386/mpr-1209 · Cited by 28
Antifungal Activity of Minocycline and Azoles Against Fluconazole-Resistant Candida Species
Tan, J., Jiang, S., Tan, L., Shi, H., Yang, L., Sun, Y., & Wang, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.649026 · Cited by 28
Zhang, M.-R., Zhao, F., Wang, S., Lv, S., Mou, Y., Yao, C.-L., Zhou, Y., & Li, F.-Q. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-4856-8 · Cited by 26
Ferreira, J. S., Lima, W. G., Parreira, A., Nascimento, L. A., Leonel, C. A., Andrade, J. T., Palumbo, J. M. C., Soares, A., & Granjeiro, P. A. (2018) · Journal of Pharmaceutical Negative Results · doi:10.4103/jpnr.jpnr_11_17 · Cited by 18
Keniya, M. V., Ruma, Y. N., Tyndall, J. D. A., & Monk, B. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01131-18 · Cited by 15
Atorvastatin Reduces the Survival of Candida albicans-Infected BALB/c Mice
Rahal, E. A., Constantin, W. N., Zeidan, N., & Abdelnoor, A. M. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01474 · Cited by 14
Angelis, G. D., Menchinelli, G., Torelli, R., Carolis, E. D., Posteraro, P., Sanguinetti, M., & Posteraro, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226467 · Cited by 12
Darma, S. H., Ambara, A., Aman, A. T., Annisa, L., Nurrokhman, Nuryastuti, T., & Wibawa, T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242542 · Cited by 10
Triazole-chalcones: Lack of antibacterial, anti-candida, and anti-dengue virus activities
Ferreira, J. S., dos Santos, M., Santos, F. R. D. S., et al. (2018) · Journal of Pharmaceutical Negative Results · doi:10.4103/jpnr.jpnr_2_18 · Cited by 9
El-Houssaini, H., Elkhatib, W., Elnabawy, O., & Nasser, H. (2019) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2019.20210 · Cited by 2
Eldesouky, H. E., Salama, E. A., Li, X., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/696773
Angelis, G. D., Menchinelli, G., Torelli, R., et al. (2019) · doi:10.1101/862078
Cited by
Repurposing of atorvastatin emulsomes as a topical antifungal agent
Eita, A. S., M. A. Makky, A., Anter, A., & Khalil, I. A. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2149898 · Cited by 24
“…an inhibition zone of 35 mm. Mahmoud et al. studied the in vitro anticandidal activity of atorvastatin alone and in combination with other conventional antifungal drugs, the microdilution method and diffusion method both proved the antifungal activity of atorvastatin (Mahmoud et al., 2021) 3.8.”
MethodInfluentialCitrus bergamia: Kinetics of Antimicrobial Activity on Clinical Isolates
Quirino, A., Giorgi, V., Palma, E., Marascio, N., Morelli, P., Maletta, A., Divenuto, F., Angelis, G. D., Tancrè, V., Nucera, S., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11030361 · Cited by 25
“Finally, Candida species (the most common opportunistic pathogen) are increasingly resistant to azole drugs with potential fungicidal effects [6].”
BackgroundAtorvastatin-loaded emulsomes foam as a topical antifungal formulation
Eita, A. S., Makky, A. M. A., Anter, A., & Khalil, I. A. H. (2022) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2022.100140 · Cited by 23
Molecular targets of insecticides and herbicides – Are there useful overlaps?
Duke, S. O., Pan, Z., Chittiboyina, A. G., Swale, D. R., & Sparks, T. C. (2023) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2023.105340 · Cited by 21
Novel avenues for identification of new antifungal drugs and current challenges
Jampílek, J. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2097659 · Cited by 21
Metadata
- Authors
- Mahmoud, D. E., Faraag, A. H. I., & Abu El-Wafa, W. M.
- Affiliations
- National Organization for Drug Control and Research (EG)
- Helwan University (EG)
- Venue
- World Journal of Microbiology and Biotechnology
- Published
- 2021-10-11
- Volume
- 37
- Issue
- 11
- Pages
- 191-191
- ISSN
- 0959-3993 (ISSN-L)
- 1573-0972
- PMC
- PMC8502632
- OpenAlex
- W3197499973
- Semantic Scholar
- f0aa44f0cd0e41033c28822191840ad6796343e2
- Cited by
- 26
- References
- 64
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 5
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- World Journal of Microbiology and Biotechnology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Agricultural and Biological Sciences › Food Science › Essential Oils and Antimicrobial Activity
- Keywords
- atorvastatin, Candida albicans, multidrug resistance, azole antifungals, fluconazole, itraconazole, ketoconazole, voriconazole, drug synergy, fungicidal activity, fungistatic activity, ERG11, lanosterol 14α-demethylase, molecular docking, combination antifungal therapy
- MeSH terms
- Atorvastatin, Animals, Antifungal Agents, Azoles, Candida albicans, Candidiasis, Fungicides, Industrial, Humans, Ketoconazole, Kinetics, Microbial Sensitivity Tests, Fluconazole, Itraconazole, Drug Resistance, Multiple, Fungal, Molecular Docking Simulation, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.